Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Enanta Pharmaceuticals ( (ENTA) ).
Enanta Pharmaceuticals announced promising topline results from their Phase 2 pediatric study of zelicapavir, a novel oral treatment for RSV, showing significant antiviral effects and a favorable safety profile. The study involved children aged 28 days to 36 months and demonstrated a notable reduction in viral load, especially in those treated within three days of symptom onset. These results highlight zelicapavir’s potential as an effective treatment for RSV, supporting further clinical evaluation.
Find detailed analytics on ENTA stock on TipRanks’ Stock Analysis page.